

Format for ANSWERING REVIEWERS



June 8, 2015

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 18744-review.doc).

Title: Helicobacter Pylori: Effect of coexisting diseases and update on treatment regimens

Author: Shen-Shong Chang and Hsiao-Yun Hu

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 18744

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

Editor Comments

Q: Please write a running title of less than 6 words. See the format in the attachment. Thank you.

A: As advised, we provided a running title of fewer than six words.

Q: Please provide the postal code.

A: As advised, we provided the postal code: 112

Q:

Authors are required to make this statement in the manuscript's title page (please see sample wording in attachment). A copy of signed statement should be provided to the BPG in PDF format.

A: As advised, we provided a copy of the signed statement to the BPG as a PDF file.

Q: Audio Core Tip

In order to attract readers to read your full-text article, we request that the first author make an audio file describing your final core tip. This audio file will be published online, along with your article. Please submit audio files according to the following specifications:

Acceptable file formats: .mp3, .wav, or .aiff

Maximum file size: 10 MB

To achieve the best quality, when saving audio files as an mp3, use a setting of 256 kbps or higher for stereo or

128 kbps or higher for mono. Sampling rate should be either 44.1 kHz or 48 kHz. Bit rate should be either 16 or 24 bit. To avoid audible clipping noise, please make sure that audio levels do not exceed 0 dBFS.

A: As advised, we provided the audio core tip for saving an audio file as an mp3.

Q: Please put the punctuation behind reference. Please check throughout. Thank you!

A: As advised, we placed the punctuation before the in-text citations throughout the manuscript.

Q: Please add PubMed citation numbers and DOI citation to the reference list and list all authors. Please revise throughout. For those references that have not been indexed by PubMed, a printed copy of the first page of the full reference should be submitted.

PMID (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed>)
DOI (<http://www.crossref.org/SimpleTextQuery/>) (Please begin with DOI: 10.**)

A: As advised, we added PubMed and DOI citation numbers to the reference list; in addition, we listed all authors.

Reviewer Number 39368

Q: This is a well written review paper concerning the prevalence of *H. pylori* and its role in increased risk of developing ulcer disease in patients with end-stage renal disease and liver cirrhosis. The authors give the extensive overview about the peculiarities of *H. pylori* prevalence and its pathogenic role in patients with concomitant diseases like end-stage renal disease and liver cirrhosis. The authors described also the optimal *H. pylori* eradication regimes in patients with concomitant diseases. The authors have reviewed and analyzed an ample amount of literature (124 references). However, the following point needs to be considered: 1. It would be necessary to mention also the possible role and prevalence of enterohepatic *Helicobacter* spp. like *Helicobacter hepaticus* and *Helicobacter bilis* in patients with concomitant diseases and particularly with liver cirrhosis.

A: We thank the reviewer for the comments and opinions. We added a section, Enterohepatic *Helicobacters* and liver disease, on page 14, lines 12–19, page 15, lines 1–19, and page 16, lines 1.

Reviewer Number 227403

Q: Main comments I think that this is a mix of at least 3 reviews: 1) *H. pylori* in ESRD 2) *H. pylori* in cirrhosis 3) updated treatments for *H. pylori* eradication. It would be better to separate these arguments (at least 1 and 2 from 3). Minor comments I think that a better title should be “Peptic ulcer disease: the role of *Helicobacter Pylori* infection in ESRD and in cirrhosis”.

A: The review article aimed to clarify the effect of coexisting diseases, such as ESRD and liver cirrhosis, on the prevalence and eradication of *H. pylori*. In addition, we summarized the updated *H. pylori* eradication therapy regimens. Therefore, we extended our discussion of the original topic: *Helicobacter Pylori*: Effect of coexisting diseases and update on treatment regimens

Q: Abstract: please clarify ESRD The authors should specify the aim.

A: As advised, we clarified ESRD on page 2, line 16-18. We also added the following to the abstract: “We aimed to review the prevalence of and eradication therapy for *H. pylori* infection in patients with ESRD and cirrhosis.” Moreover, we summarized the updated *H. pylori* eradication regimens on page 2, lines 18–19.

Q: The sentence (subtitle)“*H. pylori* prevalence among those with end-stage renal disease” should be better “*H. pylori* prevalence among patients with end-stage renal disease”

A: As advised, we modified the subtitle “*H. pylori* prevalence among patients with end-stage renal disease” on page 5, line 10.

Q: Pag 4; what is a "cutoff ECR"?

A: Huang et al. (Reference 26) assessed the accuracy of *H. pylori* diagnosis, which was analyzed using a continuous-flow isotope ratio mass spectrometer (Automatic Breath Carbon Analyzer; Europa Scientific, Crewe, UK) to determine excess $^{13}\text{CO}_2$ – $^{12}\text{CO}_2$ ratio (ECR; $-\delta^{13}\text{CO}_2$ per milliliter).

Q: Pag 10 and pag 11: metaanalysis should be meta-analysis

A: As advised, we changed the spelling to “meta-analysis” on pages 13, line 18 and page 17, line 14.

Q: Page 10: *H. pylori* infections should be infection

A: As advised, we changed the instances to *H. pylori* infection on pages 11, line 10. 11.

Q: Part of the references should be updated (starting from number 1)

A: Our aim was to review the association between *H. pylori*, ESRD, and liver cirrhosis. In addition, we discussed the updated *H. pylori* eradication therapy. Therefore, we adopted references relevant to *H. pylori* infection in patients with ESRD and cirrhosis and *H. pylori* eradication therapy. Please identify the specific references that are not updated, and we will modify them. Thank you.

Reviewer Number 410327

Q: The manuscript is quite all written. It represents a comprehensive review of the topic. It will be useful for the readers to include the discussion of PMID: 15242679 and PMID: 20695744

A: We thank the reviewer for the comment.

To Editor and All reviewers:

Reference 20 and reference 22 are similar. Therefore, we delete the original reference 22. Thanks

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

*Correspondence: Hsiao-Yun Hu, Ph.D. Institute of Public Health & Department of Public Health, National Yang Ming University, Department of Education and Research, Taipei City Hospital, No.145, Zhengzhou Rd., Taipei, Taiwan 103

E-mail: hyhu@ym.edu.tw; Tel: 886-2-27093600#3816; Fax: 886-2-28261002